Literature DB >> 8968656

Clinical pharmacokinetics of sedatives in neonates.

E Jacqz-Aigrain1, P Burtin.   

Abstract

Sedation is currently administered to neonates experiencing pain and stress during intensive care for medical diseases, as well as postoperatively. Drugs commonly used for sedation in neonates include benzodiazepines (midazolam and lorazepam), chloral hydrate and opioids (fentanyl and morphine). Sedation protocols and dosage schedules are, in most cases, adapted from those which have been developed in children and even adults. The effectiveness and safety of the sedative agents remain underevaluated, however, due to the difficulties of quantifying pain and stress in neonates, and because of the limited use of validated scoring methods by practitioners. Among the benzodiazepines, midazolam is probably the drug of choice for continuous sedation. However, its elimination is delayed in the neonatal period and hypotension may occur when given as a bolus injection or when taken with opioids. Lorazepam requires further evaluation to exclude severe neurotoxicity. Chloral hydrate is administered orally, but because of its delayed elimination and risk of accumulation, a single administration for short term sedation is recommended. Among opioids, fentanyl (which was initially administered for postoperative analgesia) is now prescribed for sedation during mechanical ventilation. Tolerance and dependence may develop rapidly, limiting its usefulness for prolonged sedation. Although extensively studied in neonates, the efficacy and safety of morphine are not clearly determined, because of the limited number of patients included in individual studies. In addition, important interindividual differences in metabolism render dosage recommendations difficult. Alfentanil and sufentanil need further investigations to define their pharmacokinetic-pharmacodynamic properties in neonates. Although the choice of drug is important, the way the drug is used and monitored is equally important. All the drugs used for the sedation of neonates have large inter- and intraindividual differences in disposition, justifying specific pharmacological knowledge and individual dosage adjustments based on clinical evaluation of the patient and the monitoring of drug concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968656     DOI: 10.2165/00003088-199631060-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  122 in total

1.  Neurotoxicity of lorazepam in a premature infant.

Authors:  C M Cronin
Journal:  Pediatrics       Date:  1992-06       Impact factor: 7.124

2.  Influence of gestational age on pharmacokinetics of alfentanil in neonates.

Authors:  A Killian; P J Davis; R L Stiller; R Cicco; D R Cook; R D Guthrie
Journal:  Dev Pharmacol Ther       Date:  1990

3.  Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion.

Authors:  J H Arnold; R D Truog; J M Scavone; T Fenton
Journal:  J Pediatr       Date:  1991-10       Impact factor: 4.406

4.  Blunting of stress responses in the pulmonary circulation of infants by fentanyl.

Authors:  P R Hickey; D D Hansen; D L Wessel; P Lang; R A Jonas; E M Elixson
Journal:  Anesth Analg       Date:  1985-12       Impact factor: 5.108

5.  Pharmacokinetics of propofol in young children after a single dose.

Authors:  C Saint-Maurice; I D Cockshott; E J Douglas; M O Richard; J L Harmey
Journal:  Br J Anaesth       Date:  1989-12       Impact factor: 9.166

6.  Effects of age on plasma protein binding of sufentanil.

Authors:  C Meistelman; D Benhamou; J Barre; J C Levron; V Mahe; X Mazoit; C Ecoffey
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

7.  The pharmacokinetics of propofol in children using three different data analysis approaches.

Authors:  B K Kataria; S A Ved; H F Nicodemus; G R Hoy; D Lea; M Y Dubois; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

8.  Pharmacokinetics of flumazenil and midazolam.

Authors:  R D Jones; K Chan; C J Roulson; A G Brown; I D Smith; G H Mya
Journal:  Br J Anaesth       Date:  1993-03       Impact factor: 9.166

Review 9.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

10.  Pain relief can reduce hypoxemia in distressed neonates during routine treatment procedures.

Authors:  M L Pokela
Journal:  Pediatrics       Date:  1994-03       Impact factor: 7.124

View more
  16 in total

Review 1.  Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit.

Authors:  Eugene Ng; Anna Taddio; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

2.  A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.

Authors:  Esther Encinas; Rosario Calvo; John C Lukas; Valvanera Vozmediano; Monica Rodriguez; Elena Suarez
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

Review 3.  Use of phenothiazines as sedatives in children: what are the risks?

Authors:  K S Dyer; A D Woolf
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

4.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

5.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 6.  Anesthesia and analgesia in the NICU.

Authors:  R Whit Hall
Journal:  Clin Perinatol       Date:  2012-03       Impact factor: 3.430

7.  Pharmacodynamics of chloral hydrate in former preterm infants.

Authors:  Karel Allegaert; Hans Daniels; Gunnar Naulaers; Dick Tibboel; Hugo Devlieger
Journal:  Eur J Pediatr       Date:  2005-03-30       Impact factor: 3.183

8.  Reduction of incarcerated inguinal hernia in infants using caudal epidural anaesthesia.

Authors:  N Brindley; R Taylor; S Brown
Journal:  Pediatr Surg Int       Date:  2005-09-14       Impact factor: 1.827

9.  Pharmacodynamics of intravenous and oral midazolam in preterm infants.

Authors:  Saskia N de Wildt; Gregory L Kearns; Sintha D Sie; Wim C J Hop; John N van den Anker
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

10.  Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units.

Authors:  Carsten Müller; Wolf Kremer; Steffi Harlfinger; Oxana Doroshyenko; Alexander Jetter; Fritz Hering; Christoph Hünseler; Bernhard Roth; Martin Theisohn
Journal:  Eur J Pediatr       Date:  2006-01-28       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.